OpenBit ResearchOpenBit
中文

What's driving BeOne Medicines (ONC)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Can BeiGene convert its pipeline into new registrational opportunities?

Why it matters now

Pipeline advancement can affect BeiGene's future product revenue and valuation; setbacks can reduce prospective value.

Next checkpoint

ONC earnings (expected 2026-11-05)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to ONC, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Key programs fail to generate adequate efficacy or safety evidence or do not advance through planned development stages.

Research drivers

  • Can BeiGene convert its pipeline into new registrational opportunities?

    Bullish · Cooling · Updated

    The pipeline is advancing across multiple programs and stages, but future value remains conditional on clinical evidence and regulatory progression.

  • Can BeiGene sustain profitable commercial growth?

    Bullish · Cooling · Updated

    The supplied quarter and raised outlook show strong commercial growth translating into higher profitability and cash generation, despite ongoing expense growth.

  • Can Brukinsa sustain a durable hematology franchise?

    Bullish · Cooling · Updated

    The supplied evidence favors durable Brukinsa efficacy and adoption, though the comparative case is not uniformly superior across every analysis.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • BeiGene completed enrollment in a potentially China registration-enabling expansion cohort for BGB-B2033 in post-IO/post-TKI HCC.

    Relayed by: Benzinga · Event date on record:

  • BeiGene raised its 2026 operating-income guidance by $250 million across the range and now expects GAAP operating income of $1.0 billion to $1.1 billion and non-GAAP operating income of $1.7 billion to $1.8 billion.

    Relayed by: Benzinga · Event date on record:

  • BeiGene reported an objective response rate of over 30% for BGB-B2033 monotherapy in second-line HCC.

    Relayed by: Benzinga · Event date on record:

  • At 400 mg, BGB-43395's overall neutropenia rate was 21%, with no grade 3 or higher events.

    Relayed by: Benzinga · Event date on record:

  • BeiGene plans to share proof-of-concept data for its PRMT5 inhibitor and CEA ADC at ESMO.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.